Clearance of Tissue Plasminogen Activator (TPA) and TPA/Plasminogen Activator Inhibitor Type 1 (PAI-1) Complex: Relationship to Elevated TPA Antigen in Patients With High PAI-1 Activity Levels

Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris

Thompson, S. G., Kienast, J., Pyke, S., Haverkate, F., & van de Loo, J. C. W. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321003 · Cited by 1,819

PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION

Hamsten, A., Walldius, G., Szamosi, A., Blombäck, M., de Faire, U., Dahlén, G. H., Landou, C., & Wiman, B. (1987) · The Lancet · doi:10.1016/s0140-6736(87)93050-9 · Cited by 1,474

Blood Transfusion in Clinical Medicine.

(1952) · JAMA · doi:10.1001/jama.1952.03680120098032 · Cited by 1,290

Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty

Shimomura, I., Funahasm, T., Takahashi, M., Maeda, K., Kotani, K., Nakamura, T., Yamashita, S., Miura, M., Fukuda, Y., Takemura, K., et al. (1996) · Nature Medicine · doi:10.1038/nm0796-800 · Cited by 889

Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study

MEADE, T. (1993) · The Lancet · doi:10.1016/0140-6736(93)92062-x · Cited by 711

Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease

Alessi, M., Peiretti, F., Morange, P., Henry, M., Nalbone, G., & Juhan-Vague, I. (1997) · Diabetes · doi:10.2337/diab.46.5.860 · Cited by 614

Endogenous tissue-type plasminogen activator and risk of myocardial infarction

Ridker, P. M., Vaughan, D. E., Manson, J., Hennekens, C. H., & Stampfer, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)90998-v · Cited by 580

Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma

Kruithof, E. K. O., Trân-Thang, C., Ransijn, A., & Bachmann, F. (1984) · Blood · doi:10.1182/blood.v64.4.907.bloodjournal644907 · Cited by 400

An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation.

Cesarman, G., Guevara, C. A., & Hajjar, K. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31948-8 · Cited by 342

Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide.

Samad, F., Yamamoto, K., & Loskutoff, D. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118404 · Cited by 301

High Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma Precede a First Acute Myocardial Infarction in Both Men and Women: Evidence for the Fibrinolytic System as an Independent Primary Risk Factor

Thögersen, A. M., Jansson, J.-H., Boman, K., Nilsson, T. K., Weinehall, L., Huhtasaari, F., & Hallmans, G. (1998) · Circulation · doi:10.1161/01.cir.98.21.2241 · Cited by 602

Diabetes mellitus as a prothrombotic condition

Grant, P. J. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01824.x · Cited by 443

Nontraditional Risk Factors and Biomarkers for Cardiovascular Disease: Mechanistic, Research, and Clinical Considerations for Youth

Balagopal, P., de Ferranti, S. D., Cook, S., Daniels, S. R., Gidding, S. S., Hayman, L. L., McCrindle, B. W., Mietus‐Snyder, M., & Steinberger, J. (2011) · Circulation · doi:10.1161/cir.0b013e31821c7c64 · Cited by 363

Adipokines, Inflammation, and Visceral Adiposity across the Menopausal Transition: A Prospective Study

Lee, C. G., Carr, M. C., Murdoch, S. J., Mitchell, E. S., Woods, N. F., Wener, M. H., Chandler, W. L., Boyko, E. J., & Brunzell, J. D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0701 · Cited by 279

Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.

Kruszynska, Y. T., Yu, J., Olefsky, J. M., & Sobel, B. E. (2000) · Diabetes · doi:10.2337/diabetes.49.4.633 · Cited by 184

Prothrombotic Coagulation Abnormalities Preceding the Hemolytic–Uremic Syndrome

Chandler, W. L., Jelačić, S., Boster, D. R., Ciol, M. A., Williams, G. D., Watkins, S. L., Igarashi, T., & Tarr, P. I. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011033 · Cited by 182

Tissue Plasminogen Activator, Plasminogen Activator Inhibitor-1, and Tissue Plasminogen Activator/Plasminogen Activator Inhibitor-1 Complex as Risk Factors for the Development of a First Stroke

Johansson, L., Jansson, J., Boman, K., Nilsson, T., Stegmayr, B., & Hallmans, G. (2000) · Stroke · doi:10.1161/01.str.31.1.26 · Cited by 169

The Vasculature in Prediabetes

Wasserman, D. H., Wang, T. J., & Brown, N. J. (2018) · Circulation Research · doi:10.1161/circresaha.118.311912 · Cited by 137

Influence of PAI-1 on Adipose Tissue Growth and Metabolic Parameters in a Murine Model of Diet-Induced Obesity

Morange, P., LIJNEN, H. R., Alessi, M., Kopp, F., Collen, D., & Juhan-Vague, I. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.4.1150 · Cited by 130

Engineering Design of Optimal Strategies for Blood Clot Dissolution

Diamond, S. L. (1999) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.1.1.427 · Cited by 129

Comparative Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Antagonism on Plasma Fibrinolytic Balance in Humans

Brown, N. J., Agirbasli, M., & Vaughan, D. E. (1999) · Hypertension · doi:10.1161/01.hyp.34.2.285 · Cited by 124

Metabolic Determinants Are Much More Important Than Genetic Polymorphisms in Determining the PAI-1 Activity and Antigen Plasma Concentrations

Henry, M., Trégouët, D., Alessi, M., Aillaud, M. F., Visvikis‐Siest, S., Siest, G., Tiret, L., & Juhan-Vague, I. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.1.84 · Cited by 121

Inflammation and thrombosis in diabetes

Hess, K., & Grant, P. J. (2011) · Thrombosis and Haemostasis · doi:10.1160/ths10-11-0739 · Cited by 117

Changes of the hemostatic network in critically ill patients-Is there a difference between sepsis, trauma, and neurosurgery patients?

Boldt, J., Papsdorf, M., Rothe, A., Kumle, B., & Piper, S. (2000) · Critical Care Medicine · doi:10.1097/00003246-200002000-00026 · Cited by 107

Injury-Specific Ex Vivo Treatment of the Donor Lung: Pulmonary Thrombolysis Followed by Successful Lung Transplantation

Machuca, T., Hsin, M. K. Y., Ott, H. C., Chen, M., Hwang, D. M., Cypel, M., Waddell, T. K., & Keshavjee, S. H. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201302-0368le · Cited by 105

Angiotensin-Converting Enzyme Inhibition Increases Human Vascular Tissue-Type Plasminogen Activator Release Through Endogenous Bradykinin

Pretorius, M., Rosenbaum, D., Vaughan, D. E., & Brown, N. J. (2003) · Circulation · doi:10.1161/01.cir.0000046268.59922.a4 · Cited by 96

An activated-platelet-sensitive nanocarrier enables targeted delivery of tissue plasminogen activator for effective thrombolytic therapy

Huang, Y., Yu, L., Ren, J., Gu, B., Longstaff, C., Hughes, A. D., Thom, S., Xu, X. Y., & Chen, R. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.02.033 · Cited by 95

Safety and Outcomes in 100 Consecutive Donation After Circulatory Death Liver Transplants Using a Protocol That Includes Thrombolytic Therapy

Bohorquez, H. E., Seal, J. B., Cohen, A. J., Kressel, A. M., Bugeaud, E., Bruce, D. S., CARMODY, I. C., Reichman, T., Battula, N. R., Alsaggaf, M. U., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14261 · Cited by 92

Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass

Chandler, W. L., & Velan, T. (2003) · Blood · doi:10.1182/blood-2002-08-2400 · Cited by 88

Low serum BDNF may indicate the development of PSD in patients with acute ischemic stroke

Yang, L., Zhang, Z., Sun, D., Xu, Z., Yuan, Y., Zhang, X., & Li, L. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2552 · Cited by 89

Platelet membrane-functionalized nanoparticles with improved targeting ability and lower hemorrhagic risk for thrombolysis therapy

Wang, S., Wang, R., Meng, N., Guo, H., Wu, S., Wang, X., Li, J., Wang, H., Jiang, K., Xie, C., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.030 · Cited by 85

The Fibrinolysis System: Regulation of Activity and Physiologic Functions of Its Main Components

Борисович, Д. А., & Владимировна, Т. Е. (2002) · Biochemistry (Moscow) · doi:10.1023/a:1013960416302 · Cited by 83

Low-Dose Tirofiban Treatment Improves Neurological Deterioration Outcome After Intravenous Thrombolysis

Wu, C., Sun, C., Wang, L., Lian, Y., Xie, N., Huang, S., Zhao, W., Ren, M., Wu, D., Ding, J., et al. (2019) · Stroke · doi:10.1161/strokeaha.119.026240 · Cited by 82

Hemostatic Activation and Outcome After Recombinant Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke

Tanné, D., Macko, R. F., Lin, Y., Tilley, B. C., & Levine, S. R. (2006) · Stroke · doi:10.1161/01.str.0000226897.43749.27 · Cited by 81

ACE Inhibition Versus Angiotensin Type 1 Receptor Antagonism

Brown, N. J., Kumar, S., Painter, C., & Vaughan, D. E. (2002) · Hypertension · doi:10.1161/01.hyp.0000040264.15961.48 · Cited by 80

Angiotensin and vascular fibrinolytic balance

Vaughan, D. A. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(01)02273-7 · Cited by 80

Coagulation, fibrinolysis, and recanalization after acute deep venous thrombosis

Meissner, M. H., Zierler, B. K., Bergelin, R. O., Chandler, W. L., & Strandness, D. E. (2002) · Journal of Vascular Surgery · doi:10.1067/mva.2002.121066 · Cited by 78

Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy

Huang, Y., Gu, B., Salles‐Crawley, I. I., Taylor, K. A., Yu, L., Ren, J., Liu, X., Emerson, M., Longstaff, C., Hughes, A. D., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf9033 · Cited by 77

Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study.

van Baal, W. M., EMEIS, J. J., van der Mooren, M. J., van Kessel, H. I., Kenemans, P., & Stehouwer, C. D. A. (2000) · PubMed · Cited by 77

Gene Polymorphism of t-PA is Associated With Forearm Vascular Release Rate of t-PA

Jern, C., Ladenvall, P., Wall, U., & Jern, S. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.2.454 · Cited by 74

Angiotensin, fibrinolysis, and vascular homeostasis

Vaughan, D. E. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01509-0 · Cited by 71

Plasminogen Activator Inhibitor Type-1 (PAI-1) and its Role in Cardiovascular Disease

Peter, K., Ruef, J., Kübler, W., Bode, C., & Nordt, T. K. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615546 · Cited by 71

Thrombus-Targeted Nanocarrier Attenuates Bleeding Complications Associated with Conventional Thrombolytic Therapy

Absar, S., Nahar, K., Kwon, Y. M., & Ahsan, F. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1011-x · Cited by 70

Markers of Coagulation and Fibrinolysis Predicting the Outcome of Acute Ischemic Stroke Thrombolysis Treatment: A Review of the Literature

Bagoly, Z., Szegedi, I., Kálmándi, R., Tóth, N. K., & Csiba, L. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00513 · Cited by 68

Tissue-type Plasminogen Activator –7,351C/T Enhancer Polymorphism Is Associated with a First Myocardial Infarction

Jansson, J., Jern, S., Nilsson, T. K., Tjärnlund, A., Boman, K., Ladenvall, P., Johansson, L., & Jern, C. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1612951 · Cited by 69

Equipoise among recanalization strategies

Tomsick, T. A., Khatri, P., Jovin, T. G., Demaerschalk, B. M., Malisch, T. W., Demchuk, A. M., Hill, M. D., Jauch, E. C., Spilker, J. A., & Broderick, J. P. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d76b8f · Cited by 67

Exposure to nitrogen dioxide is not associated with vascular dysfunction in man

Langrish, J. P., Lundbäck, M., Barath, S., Söderberg, S., Mills, N. L., Newby, D. E., Sandström, T., & Blomberg, A. (2010) · Inhalation Toxicology · doi:10.3109/08958370903144105 · Cited by 66

Innovative thrombolytic strategy using a heterodimer diabody against TAFI and PAI-1 in mouse models of thrombosis and stroke

Wyseure, T. L., Rubio, M., Denorme, F., de Lizarrondo, S. M., Peeters, M., Gils, A., Meyer, S. F. D., Vivien, D., & Declerck, P. J. (2014) · Blood · doi:10.1182/blood-2014-07-588319 · Cited by 67

Magnetically active Fe3O4 nanorods loaded with tissue plasminogen activator for enhanced thrombolysis

Hu, J., Huang, W., Huang, S., Zhuge, Q., Jin, K., & Zhao, Y. (2016) · Nano Research · doi:10.1007/s12274-016-1152-4 · Cited by 69

Effect of Combination Glipizide GITS/Metformin on Fibrinolytic and Metabolic Parameters in Poorly Controlled Type 2 Diabetic Subjects

Cefalu, W. T., Schneider, D. J., Carlson, H. E., Migdal, P., Lim, L. G., Izon, M. P., Kapoor, A., Bell–Farrow, A. D., Terry, J. G., & Sobel, B. E. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2123 · Cited by 65

Human tissue-type plasminogen activator

Kruithof, E. K. O., & Dunoyer-Geindre, S. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-06-0517 · Cited by 63

The antithrombotic effect of dextran-40 in man is due to enhanced fibrinolysis in vivo

Jones, C. I., Payne, D. A., Hayes, P. D., Naylor, A. R., Bell, P. R. F., Thompson, M. M., & Goodall, A. H. (2008) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2008.04.008 · Cited by 63

Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: A randomized placebo-controlled study

Post, M. S., van der Mooren, M. J., van Baal, W. M., Blankenstein, M. A., Merkus, H. M. W. M., Kroeks, M. V. A. M., Franke, H. R., Kenemans, P., & Stehouwer, C. D. A. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/s0002-9378(03)00599-4 · Cited by 63

Tissue Plasminogen Activator Antigen and D-Dimer as Markers for Atherothrombotic Risk Among Healthy Postmenopausal Women

Pradhan, A. D., LaCroix, A. Z., Langer, R. D., Trevisan, M., Lewis, C. E., Hsia, J. A., Oberman, A., Kotchen, J. M., & Ridker, P. M. (2004) · Circulation · doi:10.1161/01.cir.0000134965.73212.a6 · Cited by 60

Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome

Carmassi, F., Negri, F. D., Fioriti, R., Giorgi, A. D., Giannarelli, C., Fruzzetti, F., Pedrinelli, R., Dell’Omo, G., & Bersi, C. (2005) · Thrombosis Research · doi:10.1016/j.thromres.2004.11.026 · Cited by 62

The role of fibrinogen and fibrinolysis in peripheral arterial disease

Paraskevas, K. I., Baker, D., Vrentzos, G. E., & Mikhailidis, D. P. (2007) · Thrombosis Research · doi:10.1016/j.thromres.2007.06.003 · Cited by 60

Identification of Eight Novel Single-Nucleotide Polymorphisms at Human Tissue-type Plasminogen Activator (t-PA) Locus: Association with Vascular t-PA Release In Vivo

Ladenvall, P., Wall, U., Jern, S., & Jern, C. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613990 · Cited by 60

Coagulation and fibrinolysis in patients undergoing operation for ruptured and nonruptured infrarenal abdominal aortic aneurysms

Adam, D. J., Ludlam, C. A., Ruckley, C. V., & Bradbury, A. W. (1999) · Journal of Vascular Surgery · doi:10.1016/s0741-5214(99)70103-5 · Cited by 59

Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin

Kwaan, H. C., Wang, J., & Weiss, I. M. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7933.2004.00593.x · Cited by 58

The l-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man

Newby, D. E., Wright, R. A., Dawson, P., Ludlam, C. A., Boon, N. A., Fox, K. A. A., & Webb, D. J. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00017-0 · Cited by 58

Exercise training enhances endogenous fibrinolysis in peripheral arterial disease

Killewich, L. A., Macko, R. F., Montgomery, P. S., Wiley, L. A., & Gardner, A. W. (2004) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2004.07.030 · Cited by 55

Relationship between Visceral Fat and PAI-1 in Overweight Men and Women before and after Weight Loss

Kockx, M., Leenen, R. C. A., Seidell, J. C., Princen, H. M. G., & Kooistra, T. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614860 · Cited by 56

Functional plasminogen activator inhibitor 1 is retained on the activated platelet membrane following platelet activation

Morrow, G. B., Whyte, C. S., & Mutch, N. J. (2019) · Haematologica · doi:10.3324/haematol.2019.230367 · Cited by 55

The Role of the t-PA I/D and PAI-1 4G/5G Polymorphisms in African-American Adults With a Diagnosis of Myocardial Infarction or Venous Thromboembolism

Hooper, W. C., Lally, C. A., Austin, H. D., Renshaw, M. A., Dilley, A., WENGER, N. K., Phillips, D. J., Whitsett, C., Rawlins, P., & Evatt, B. L. (2000) · Thrombosis Research · doi:10.1016/s0049-3848(00)00236-x · Cited by 55

Effects of Hemodilution, Blood Loss, and Consumption on Hemostatic Factor Levels During Cardiopulmonary Bypass

Chandler, W. L. (2005) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2004.11.046 · Cited by 53

Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome― Fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction

Wada, T., Gando, S., Mizugaki, A., Yanagida, Y., Jesmin, S., Yokota, H., & Ieko, M. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.05.010 · Cited by 52

The role of haematological factors in diabetic peripheral arterial disease: the Edinburgh Artery Study

Lee, A. J., MacGregor, A. S., Hau, C. M., Price, J. F., Rumley, A., Lowe, G. D. O., & Fowkes, F. G. R. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01382.x · Cited by 51

Thrombus-specific/responsive biomimetic nanomedicine for spatiotemporal thrombolysis and alleviation of myocardial ischemia/reperfusion injury

Guo, X., Hong, T., Zang, J., Shao, R., Hou, X., Wang, K., Liu, W., Su, F., & He, B. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01686-1 · Cited by 50

Secretion of tissue plasminogen activator and plasminogen activator inhibitor 1 during cardiopulmonary bypass

Chandler, W. L., & Velan, T. (2003) · Thrombosis Research · doi:10.1016/j.thromres.2003.11.006 · Cited by 48

Stroke outcomes with use of antithrombotics within 24 hours after recanalization treatment

Jeong, H., Kim, B. J., Yang, M., Han, M., Bae, H., & Lee, S. (2016) · Neurology · doi:10.1212/wnl.0000000000003083 · Cited by 48

Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia

Grünewald, M., Siegemund, A., Grünewald, A., Konegen, A., Koksch, M., & Grießhammer, M. (2002) · Haemophilia · doi:10.1046/j.1365-2516.2002.00686.x · Cited by 48

Associations between insulin resistance and thrombotic risk factors in high‐risk South Asian subjects

Kain, K., Catto, A. J., & Grant, P. J. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00958.x · Cited by 48

Elevated Tissue Plasminogen Activator Antigen and Stroke Risk

Macko, R. F., Kittner, S. J., Epstein, A. E., Cox, D. K., Wozniak, M. A., Wityk, R. J., Stern, B. J., Sloan, M. A., Sherwin, R. W., Price, T. R., et al. (1999) · Stroke · doi:10.1161/01.str.30.1.7 · Cited by 48

Intracellular tPA–PAI-1 interaction determines VLDL assembly in hepatocytes

Dai, W., Zhang, H., Lund, H., Zhang, Z., Castleberry, M., Rodriguez, M., Kuriakose, G., Gupta, S. K., Lewandowska, M., Powers, H. R., et al. (2023) · Science · doi:10.1126/science.adh5207 · Cited by 52

Application of Nanotechnology in Thrombus Therapy

Zhou, S., Zhao, W., Hu, J., Mao, C., & Zhou, M. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202202578 · Cited by 49

Oral, but Not Transdermal, Administration of Estrogens Lowers Tissue-Type Plasminogen Activator Levels in Humans Without Affecting Endothelial Synthesis

Giltay, E. J., Gooren, L. J., EMEIS, J. J., Kooistra, T., & Stehouwer, C. D. A. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.5.1396 · Cited by 45

Heterogeneous glycosylation patterns of human PAI-1 may reveal its cellular origin

Brogren, H., Sihlbom, C., Wallmark, K., Lönn, M., Deinum, J., Karlsson, L., & Jern, S. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2008.04.008 · Cited by 46

Progressive intermittent claudication is associated with impaired fibrinolysis

Killewich, L. A., Gardner, A. W., Macko, R. F., Hanna, D. J., Goldberg, A. P., Cox, D. K., & Flinn, W. R. (1998) · Journal of Vascular Surgery · doi:10.1016/s0741-5214(98)70229-0 · Cited by 46

Ultrasound-responsive theranostic platform for the timely monitoring and efficient thrombolysis in thrombi of tPA resistance

Lin, L., Ba, Z., Tian, H., Qin, H., Chen, X., Zhou, X., Zhao, S., Li, L., Xue, F., Li, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50741-y · Cited by 50

Genetic variation at the human tissue-type plasminogen activator (tPA) locus: haplotypes and analysis of association to plasma levels of tPA

Ladenvall, P., Nilsson, S., Jood, K., Rosengren, A., Blomstrand, C., & Jern, C. (2003) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201011 · Cited by 44

Interacting hepatic PAI-1/tPA gene regulatory pathways influence impaired fibrinolysis severity in obesity

Zheng, Z., Nakamura, K., Gershbaum, S., Wang, X., Thomas, S., Bessler, M., Schrope, B., Krikhely, A., Liu, R.-M., Ozcan, L., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci135919 · Cited by 43

Plasmatic coagulation and fibrinolytic system alterations in PNH

Grünewald, M., Siegemund, A., Grünewald, A., Schmid, A., Koksch, M., Schöpflin, C., Schauer, S., & Grießhammer, M. (2003) · Blood Coagulation & Fibrinolysis · doi:10.1097/00001721-200310000-00011 · Cited by 42

Effect of Combined AT1Receptor and Aldosterone Receptor Antagonism on Plasminogen Activator Inhibitor-1

Sawathiparnich, P., Murphey, L. J., Kumar, S., Vaughan, D. E., & Brown, N. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030374 · Cited by 42

Measurement of Different Forms of Tissue Plasminogen Activator in Plasma

Chandler, W. L., Jascur, M. L., & Henderson, P. J. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.1.38 · Cited by 42

Evaluation of PAI-039 [{1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1 H-indol-3-yl}(oxo)acetic Acid], a Novel Plasminogen Activator Inhibitor-1 Inhibitor, in a Canine Model of Coronary Artery Thrombosis

Hennan, J. K., Elokdah, H. M., Leal, M., Ji, A., Friedrichs, G. S., Morgan, G. A., Swillo, R. E., Antrilli, T. M., Hreha, A. L., & Crandall, D. L. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084129 · Cited by 42

Association between gaseous air pollutants and inflammatory, hemostatic and lipid markers in a cohort of midlife women

Wu, X., Basu, R., Malig, B. J., Broadwin, R., Ebisu, K., Gold, E. B., Qi, L., Derby, C. A., & Green, R. (2017) · Environment International · doi:10.1016/j.envint.2017.07.004 · Cited by 41

A critical review on marine serine protease and its inhibitors: A new wave of drugs?

Barzkar, N., Khan, Z., Jahromi, S. T., Pourmozaffar, S., Gozari, M., & Nahavandi, R. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.12.134 · Cited by 43

Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women

Koh, K. K., Horne, M. K., Csákó, G., Waclawiw, M. A., & Cannon, R. O. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00891-1 · Cited by 40

Fibrinolytic function and atrial fibrillation

Marín, F. R., Roldán, V., & Lip, G. Y. H. (2003) · Thrombosis Research · doi:10.1016/s0049-3848(03)00259-7 · Cited by 39

Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis

Zheng, Z., Mukhametova, L. I., Boffa, M. B., Moore, E. E., Wolberg, A. S., Urano, T., & Kim, P. Y. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.01.008 · Cited by 44

Hemodynamic, hemostatic, and endothelial reactions to psychological and physical stress in coronary artery disease patients

Bacon, S., Ring, C., Li‐Saw‐Hee, F. L., Lip, G. Y. H., Blann, A. D., Lavoie, K., & Carroll, D. (2005) · Biological Psychology · doi:10.1016/j.biopsycho.2005.03.003 · Cited by 38

A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis

Hayakawa, M., Sawamura, A., Gando, S., Jesmin, S., Naito, S., & Ieko, M. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.01.015 · Cited by 36

Engineering of plasminogen activators for targeting to thrombus and heightening thrombolytic efficacy

Absar, S., Gupta, N., Nahar, K., & Ahsan, F. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13033 · Cited by 36

The Fibrinolytic System: Mysteries and Opportunities

Medcalf, R. L., & Keragala, C. B. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000570 · Cited by 36

Heparin-triggered release of camouflaged tissue plasminogen activator for targeted thrombolysis

Absar, S., Choi, S.-A., Yang, V. C.-M., & Kwon, Y. M. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.060 · Cited by 36

Association of genetic variants of fibrinolytic system with stroke and stroke subtypes

Babu, M. S., Prabha, T. S., Kaul, S., Al‐Hazzani, A. A., Shafi, G., Roy, S., Balakrishna, N., Jyothy, A., & Munshi, A. (2012) · Gene · doi:10.1016/j.gene.2011.12.046 · Cited by 35

RGD Modified Protein–Polymer Conjugates for pH-Triggered Targeted Thrombolysis

Li, B., Chen, R., Zhang, Y., Zhao, L., Liang, H., Yan, Y., Tan, H. F., Nan, D., Jin, H., & Huang, Y. (2018) · ACS Applied Bio Materials · doi:10.1021/acsabm.8b00644 · Cited by 34

Surface modification of PVDF using non-mammalian sources of collagen for enhancement of endothelial cell functionality

Wang, J. K., Xiong, G. M., Luo, B., Choo, C. C., Yuan, S., Tan, N. S., & Choong, C. S. N. (2016) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-015-5651-8 · Cited by 33

Fibrinolytic function and coronary risk

Juhan-Vague, I., Morange, P., & Alessi, M. (1999) · Current Cardiology Reports · doi:10.1007/s11886-999-0069-x · Cited by 33

Catheter directed compared to systemically delivered thrombolysis for pulmonary embolism: a systematic review and meta-analysis

Pasha, A. K., Siddiqui, M. U., Siddiqui, M. D., Ahmed, A., Abdullah, A., Riaz, I. B., Murad, M. H., Bjarnason, H., Wysokiński, W. E., & McBane, R. D. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02556-7 · Cited by 32

Activation of fibrinolytic pathways is associated with duration of supraceliac aortic cross-clamping

Haithcock, B. E., Shepard, A. D., Raman, S. B. K., Conrad, M. F., Pandurangi, K., & Fanous, N. H. (2004) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2004.04.015 · Cited by 32

A Single Bout of Walking Exercise Enhances Endogenous Fibrinolysis in Stroke Patients

Ivey, F. M., Womack, C. J., Kulaputana, O., Dobrovolny, C. L., Wiley, L. A., & Macko, R. F. (2003) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000048634.89370.06 · Cited by 32

Plasminogen Activator Inhibitor Type 1 in Ischemic Cardiomyopathy

Cesari, M., & Rossi, G. P. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.6.1378 · Cited by 32

Intraoperative Diagnosis of Intracardiac Thrombus During Orthotopic Liver Transplantation With Transesophageal Echocardiography: A Case Series and Literature Review

Dalia, A. A., Khan, H., & Flores, A. S. (2016) · Seminars in Cardiothoracic and Vascular Anesthesia · doi:10.1177/1089253216677966 · Cited by 31

Thrombin-responsive engineered nanoexcavator with full-thickness infiltration capability for pharmaceutical-free deep venous thrombosis theranostics

Yang, A., Qiao, B., Strohm, E. M., Cao, J., Wang, Z., Yuan, X. F., Luo, Y., & Sun, Y. (2020) · Biomaterials Science · doi:10.1039/d0bm00917b · Cited by 31

Temporal Changes in tPA and PAI-1 after Maximal Exercise

Cooper, J. A., Nagelkirk, P. R., Coughlin, A. M., Pivarnik, J. M., & Womack, C. J. (2004) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000145447.61736.ed · Cited by 30

Myocardial ischemia induces coronary t‐PA release in the pig

Österlund, B., Andersson, B., Häggmark, S., Jern, C., JOHANSSON, G., Seeman-Lodding, H., & Biber, B. (2002) · Acta Anaesthesiologica Scandinavica · doi:10.1034/j.1399-6576.2002.t01-1-460308.x · Cited by 30

Prospective study of the incidence and predictors of thrombus in children undergoing palliative surgery for single ventricle physiology

Tzanetos, D. T., Yu, C., Hernanz‐Schulman, M., Barr, F. E., & Brown, N. J. (2011) · Intensive Care Medicine · doi:10.1007/s00134-011-2378-y · Cited by 29

Haemostatic function, arterial disease and the prevention of arterial thrombosis

MacCallum, P. K., & Meade, T. W. (1999) · Best Practice & Research Clinical Haematology · doi:10.1053/beha.1999.0041 · Cited by 29

Recombinant T Cell Receptor Ligand Treatment Improves Neurological Outcome in the Presence of Tissue Plasminogen Activator in Experimental Ischemic Stroke

Zhu, W., Libal, N. L., Casper, A., Bodhankar, S., Offner, H., & Alkayed, N. J. (2014) · Translational Stroke Research · doi:10.1007/s12975-014-0348-8 · Cited by 28

Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system.

Wing, L. R., Gm, H., Bennett, B., & Booth, N. A. (1991) · PubMed · Cited by 39

Hepatic clearance of tissue plasminogen activator (t-PA) : the role of PAI-1

Wing, L. R. (1991)

Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states

Niwano, H., Takahashi, H., Tatewaki, W., Wada, K., Seki, Y., & Shibata, A. (1992) · Blood Coagulation & Fibrinolysis · doi:10.1097/00001721-199203040-00005 · Cited by 6

Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma

Chandler, W. L., Trimble, S., Loo, S., & Mornin, D. (1990) · Blood · doi:10.1182/blood.v76.5.930.930 · Cited by 111

The role of plasminogen activator inhibitor type 1 in the clearance of tissue-type plasminogen activator by rat hepatoma cells.

Camani, C., Bachmann, F., & Kruithof, E. K. O. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37528-2 · Cited by 28